Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Parallel Group Study to Evaluate the Effect of Six Weeks of Treatment With Nasal Spray (NS) ZT-034, Compared to Subcutaneous (SC) Forteo and Placebo, on Bone Formation, as Assessed by Stimulation of Serum P1NP Levels in Postmenopausal Women With Low Bone Mass

NCT01604057 is registered in ClinicalTrials.gov with Azelon Pharmaceuticals as lead sponsor.

NCT NCT01604057
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01604057 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Parallel Group Study to Evaluate the Effect of Six Weeks of Treatment With Nasal Spray (NS) ZT-034, Compared to Subcutaneous (SC) Forteo and Placebo, on Bone Formation, as Assessed by Stimulation of Serum P1NP Levels in Postmenopausal Women With Low Bone Mass
Lead sponsor
Azelon Pharmaceuticals
Phase
Phase 2
Overall status
Unknown status
Start date
November 30, 2011
Completion date
July 31, 2012
Enrollment
130 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

osteopenia, osteoporosis